Vivani Medical, Inc. VANI
Set alert
As of Nov 2, 11:15 AM ET
- YTD
- -8.13%
- 1 year
- -29.81%
- Open
- 1.13
- Prev close
- 1.09
- Mkt cap
- 101.48M
- Vol
- 34.64K
- Avg vol
- 194.26K
- EPS
- -0.36
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.12
- High
- 1.16
- Forward P/E
- -2.11
- Beta
- 3.52
- Short ratio
- 12.59
- Inst. own
- 10.47%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.30
- 200-d avg
- 1.46
- 1y target
- 5.50
News
-
2 months ago benzinga.com
Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of…
-
3 months ago benzinga.com
Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant
NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani’s proprietary…
-
4 months ago benzinga.com
ClearOne To Acquire Vivani Medical Subsidiary Cortigent For 12.5M Shares Of CLRO Worth ~$40.4M; ClearOne To File S-1 Seeking To Raise $10M-$15M
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it has entered into a definitive…
-
4 months ago benzinga.com
Vivani Medical Receives Approval From Australian Human Research Ethics Committee Bellberry To Initiate SLIM-1, A Phase 1 Clinical Trial Of Semaglutide Implant NPM-139
Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks an important moment for our Company, clearing the way for near-term, mid-2026, initiation. We are eager…
-
4 months ago benzinga.com
Lake Street Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $4
Lake Street analyst Thomas Flaten initiates coverage on Vivani Medical (NASDAQ:VANI) with a Buy rating and announces Price Target of $4.
6 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
7 months ago benzinga.com
Vivani Medical Q4 EPS $(0.09) Beats $(0.10) Estimate.
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 18.18 percent increase over losses of $(0.11)…
-
9 months ago benzinga.com
Vivani's Brain Implant Helps Blind Patients See Light And Movement In 6-Year Study
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc.…
-
11 months ago benzinga.com
Vivani Medical Q3 EPS $(0.11), Inline
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
-
11 months ago benzinga.com
Vivani Medical Expects To Spin Off Cortigent Unit; Starts Clinical Development Of NPM-139 Semaglutide Implant In Obesity, Chronic Weight Management In 2026
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reported financial results for the third…
-
11 months ago benzinga.com
Vivani Medical Announces Company Presentation, Unveils Obesity Market Strategy With New GLP-1 Implant Technology
https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/pdf/Vivani+Corporate+Presentation+_+102925.pdf
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
Vivani Sets October 8 Record Date For Spin-Off Of Cortigent, To Trade Under Nasdaq Ticker 'CRGT'
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
Vivani Medical Plans To Initiate Phase 1 Clinical Study In NPM-139 Semaglutide Implant Program In First Half Of 2026, Pending Regulatory Clearance
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirst-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
-
1 year ago benzinga.com
Vivani Medical Q2 EPS $(0.12) Misses $(0.10) Estimate
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 20 percent decrease over losses of $(0.10)…
1 year ago benzinga.com
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
Vivani Medical Announces The Appointment Of Anthony Baldor As Chief Financial Officer
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
Vivani Medical Q1 EPS $(0.11) Misses $(0.10) Estimate
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 8.33 percent increase over losses of…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
-
1 year ago benzinga.com
Vivani Medical Expands Collaboration With Okava Pharmaceuticals To Include Dogs In Development Of OKV-119, A Long-Acting Glp-1 Therapy For Weight Management, Diabetes and Other Cardiometabolic Conditions
ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature,…
1 year ago benzinga.com
EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs
Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
-
1 year ago benzinga.com
Vivani Medical Q4 2024 GAAP EPS $(0.11), Inline, As Of December 31, 2024, Vivani Had Cash, Cash Equivalents And Restricted Cash Totaling $19.7M, Additional $8.25M Equity Financing Which Secures Solid Financial Position Into Q2 Of 2026
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 8.33 percent increase over losses of $(0.12) per share from the same…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
1 year ago benzinga.com
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.
1 year ago benzinga.com
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
1 year ago benzinga.com
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.
-
1 year ago benzinga.com
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic
-
1 year ago benzinga.com
'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf
-
2 years ago benzinga.com
Reported Earlier, 'Novo Nordisk's Ozempic and Wegovy, long in shortage, are now listed as available by FDA; It remains unclear how the update could affect patients as well as compounders' - STAT News
https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/
-
2 years ago benzinga.com
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
2 years ago benzinga.com
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of…
-
2 years ago benzinga.com
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
-
2 years ago benzinga.com
BigBear.ai And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed higher by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…
-
3 years ago benzinga.com
Martin Midstream Partners And 3 Other Penny Stocks Insiders Are Buying
The Dow Jones closed higher by over 200 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
3 years ago benzinga.com
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
-
4 years ago benzinga.com
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.